Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs HYDROXYZINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Triprolidine is a first-generation antihistamine that competes with histamine for H1-receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a nasal decongestant via alpha-adrenergic receptor activation, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing antitussive effects by suppressing the cough center in the medulla.
Hydroxyzine hydrochloride is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors. It also possesses anticholinergic, antiemetic, and sedative properties. Its mechanism involves binding to H1 receptors in the gastrointestinal tract, uterus, blood vessels, and bronchial muscles, thereby inhibiting histamine-mediated effects.
FDA: Relief of symptoms of upper respiratory allergies and common cold, including nasal congestion, runny nose, sneezing, and cough.,Off-label: Not commonly used off-label due to abuse potential.
Pruritus due to urticaria (FDA),Anxiety and tension (FDA),Preoperative sedation (FDA),Nausea and vomiting (off-label),Allergic rhinitis (off-label),Insomnia (off-label)
Each 5 m L oral solution contains triprolidine HCl 1.25 mg, pseudoephedrine HCl 30 mg, and codeine phosphate 10 mg. Adult dose: 10 m L (2 teaspoonfuls) every 4 to 6 hours, not to exceed 40 m L in 24 hours.
25-100 mg orally or intramuscularly 3-4 times daily; maximum 600 mg/day.
Triprolidine: 3-6 hours (increased in elderly). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine; up to 16 hours at p H 8). Codeine: 2.5-3.5 hours (terminal half-life; morphine metabolite ~2-3 hours).
Terminal elimination half-life is approximately 20-25 hours in adults. In elderly or hepatic impairment, may be prolonged. Clinical context: Achieves steady-state after ~4-5 days; detectable for >72 hours after cessation.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min), administer every 8-12 hours and reduce dose by 25-50%. Monitor for excessive sedation and respiratory depression.
No specific dose adjustment required; however, use with caution and consider reducing dose in severe renal impairment (Cr Cl < 10 m L/min) due to risk of accumulation.
Codeine is contraindicated for post-operative pain management in children undergoing tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death. Codeine is contraindicated in children under 12 years of age for treatment of pain or cough. The combination product should not be used in children under 18 years of age due to risks of respiratory depression, addiction, and accidental overdose.
First trimester: Codeine phosphate is associated with increased risk of congenital malformations, particularly cardiovascular defects, in some studies; pseudoephedrine may be linked to gastroschisis; triprolidine hydrochloride has limited data but low risk. Second/third trimester: Codeine can cause neonatal respiratory depression and withdrawal if used near term; pseudoephedrine may reduce placental blood flow. All trimesters: Avoid due to potential fetal harm; use only if benefit clearly outweighs risk.
Hydroxyzine hydrochloride is a pregnancy category C drug. First trimester: limited human data suggest a possible increased risk of congenital malformations, but risk cannot be excluded. Animal studies have shown teratogenic effects at high doses. Second and third trimesters: no evidence of fetal harm from controlled human studies, but avoid use near term due to potential neonatal adverse effects (e.g., respiratory depression, hypotonia, withdrawal symptoms).
Triprolidine is a first-generation antihistamine with sedative properties; pseudephedrine is a sympathomimetic decongestant; codeine is an opioid antitussive. Monitor for CNS depression and respiratory depression, especially when combined with other depressants. Avoid use in children under 18 years due to risk of serious breathing problems with codeine. Use with caution in hypertension, hyperthyroidism, and MAOI use. Antihistamine anticholinergic effects may worsen urinary retention or glaucoma. Codeine is a prodrug metabolized by CYP2D6; ultrarapid metabolizers risk toxicity.
Hydroxyzine hydrochloride is an antihistamine with sedative, anxiolytic, and antiemetic properties. It is contraindicated in patients with prolonged QT interval or those taking other QT-prolonging drugs due to risk of torsades de pointes. Onset of sedation occurs within 15-30 minutes; avoid driving or operating heavy machinery. For pruritus, it is more effective than diphenhydramine but causes less drowsiness at lower doses. Rapid IV administration can cause hemolysis; administer IM only. In elderly patients, risk of dizziness and falls is increased; use with caution.
No interactions on record
No interactions on record
Common clinical questions about TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs HYDROXYZINE HYDROCHLORIDE, answered by our medical review team.
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE is a Antihistamine that works by Triprolidine is a first-generation antihistamine that competes with histamine for H1-receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a nasal decongestant via alpha-adrenergic receptor activation, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing antitussive effects by suppressing the cough center in the medulla.. HYDROXYZINE HYDROCHLORIDE is a Antihistamine that works by Hydroxyzine hydrochloride is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors. It also possesses anticholinergic, antiemetic, and sedative properties. Its mechanism involves binding to H1 receptors in the gastrointestinal tract, uterus, blood vessels, and bronchial muscles, thereby inhibiting histamine-mediated effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE and HYDROXYZINE HYDROCHLORIDE depend on the specific clinical indication. These are both Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE is: Each 5 m L oral solution contains triprolidine HCl 1.25 mg, pseudoephedrine HCl 30 mg, and codeine phosphate 10 mg. Adult dose: 10 m L (2 teaspoonfuls) every 4 to 6 hours, not to exceed 40 m L in 24 hours.. The standard adult dose of HYDROXYZINE HYDROCHLORIDE is: 25-100 mg orally or intramuscularly 3-4 times daily; maximum 600 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE and HYDROXYZINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE is classified as Category A/B. First trimester: Codeine phosphate is associated with increased risk of congenital malformations, particularly cardiovascular defects, in some studies; pseudoephedrine may be linke. HYDROXYZINE HYDROCHLORIDE is classified as Category A/B. Hydroxyzine hydrochloride is a pregnancy category C drug. First trimester: limited human data suggest a possible increased risk of congenital malformations, but risk cannot be excl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Triprolidine undergoes hepatic metabolism via CYP450 enzymes, primarily CYP3A4. Pseudoephedrine is partially metabolized in the liver by N-demethylation via CYP2D6. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine. UGT2B7 also participates in metabolism.
Hydroxyzine is extensively metabolized in the liver primarily via CYP3A4 and CYP2D6 enzymes. The major metabolite is cetirizine, which is pharmacologically active. Additional minor metabolites include oxycetirizine and p-hydroxyhydroxyzine.
Triprolidine: predominantly renal (85% as metabolites, <5% unchanged). Pseudoephedrine: renal (70-90% unchanged, dependent on urine p H). Codeine: renal (86% total, 5-15% unchanged, rest as conjugates and metabolites including morphine).
Primarily hepatic metabolism via CYP3A4 and CYP3A5; <1% excreted unchanged in urine. Renal elimination of metabolites (approx. 50-60% of total clearance), with minor fecal excretion (<10%).
Triprolidine: ~60-70% (serum proteins). Pseudoephedrine: negligible (<10%). Codeine: ~25-30% (primarily albumin).
93% bound primarily to albumin, with some binding to alpha-1-acid glycoprotein.
Triprolidine: ~2-3 L/kg. Pseudoephedrine: ~2.6-3.5 L/kg. Codeine: ~3-4 L/kg.
Approximately 7-16 L/kg (range 7-16 L/kg). Large Vd indicates extensive tissue distribution, including CNS.
Oral: Triprolidine ~80-90%; Pseudoephedrine ~90-100% (first-pass minimal); Codeine ~50% (extensive first-pass metabolism to morphine and other metabolites).
Oral: approximately 70-80% due to first-pass metabolism, but variable. IM: 100% (complete absorption).
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend dosing interval to every 8 hours. Child-Pugh Class C: Avoid use due to risk of encephalopathy and accumulation of codeine.
In Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use or reduce dose by 75%.
Children 6-12 years: 5 m L (1 teaspoonful) every 4-6 hours, not to exceed 20 m L in 24 hours. Children 12-18 years: same as adult dosing (10 m L every 4-6 hours, max 40 m L daily). Contraindicated in children <6 years due to risk of respiratory depression.
Children > 6 years: 0.5-1 mg/kg/dose orally or IM every 4-6 hours as needed; maximum 100 mg/day.
Initiate at 5 m L every 6-8 hours due to increased sensitivity to anticholinergic effects, sedation, and respiratory depression. Monitor for confusion, urinary retention, and hypotension. Avoid in patients with cognitive impairment or falls risk.
Initiate at 25 mg orally or IM 3-4 times daily; titrate slowly due to increased risk of sedation, anticholinergic effects, and falls.
No FDA black box warnings.
Respiratory depression, especially in children and elderly; risk of opioid abuse, addiction, and diversion; severe hypotension; serotonin syndrome with concurrent serotonergic drugs; CNS depression; exacerbation of glaucoma, prostatic hypertrophy, or urinary retention; hypertension; increased intraocular pressure; hyperthyroidism; diabetes mellitus; ischemic heart disease; driving impairment; avoid alcohol; use with caution in patients with asthma, COPD, or other chronic respiratory conditions.
Hypersensitivity to any component; children under 18 years of age; severe hypertension; severe coronary artery disease; MAOI use within 14 days; acute or severe bronchial asthma; gastrointestinal obstruction; urinary retention; narrow-angle glaucoma; breastfeeding (due to codeine); concomitant use with other CNS depressants including alcohol; history of substance abuse; respiratory depression; suspected prior opioid tolerance.
Avoid alcohol and grapefruit juice (may affect metabolism). Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs concurrently. Caffeine may exacerbate side effects like nervousness.
No clinically significant food interactions. However, alcohol should be avoided as it potentiates the sedative effects of hydroxyzine.
Codeine is excreted into breast milk; M/P ratio approximately 2.5; risk of neonatal CNS depression, especially in CYP2D6 ultra-rapid metabolizers (can produce toxic morphine levels). Pseudoephedrine passes into milk, may cause irritability or decreased milk supply. Triprolidine is excreted in small amounts but may cause drowsiness. Contraindicated during breastfeeding due to codeine.
Hydroxyzine is excreted into human milk in small amounts. M/P ratio is approximately 0.6. Caution is advised; use during breastfeeding only if clearly needed. Monitor infant for drowsiness, irritability, or feeding difficulties. The American Academy of Pediatrics considers hydroxyzine compatible with breastfeeding.
No specific dose adjustment recommendations due to contraindication; pharmacokinetic changes in pregnancy (e.g., increased clearance of codeine via CYP2D6 and glucuronidation, but fetal toxicity risk outweighs any possible benefit). Do not use during pregnancy.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy, but individualize dose due to potential volume of distribution increases. Use the lowest effective dose for the shortest duration. Avoid high doses in the third trimester due to risk of neonatal withdrawal.
Do not exceed recommended doses; may cause drowsiness, avoid driving.,Do not use with alcohol or other sedatives.,Report difficulty breathing, slow heartbeat, or severe dizziness.,Do not use in children under 18 years.,Avoid prolonged use; if symptoms persist, consult physician.,Store at room temperature, away from moisture and heat.
May cause drowsiness; avoid driving or operating heavy machinery until you know how the drug affects you.,Avoid alcohol and other CNS depressants as they can increase drowsiness.,If you have an allergy to hydroxyzine or cetirizine, do not take this medication.,Notify your doctor if you have a history of heart problems (QT prolongation), liver disease, or seizures.,Take exactly as prescribed; do not increase dose without consulting your doctor.,For itching, use as directed; if symptoms persist, contact your healthcare provider.